Peptide Therapy for Hair Growth: Evidence, Types & Clinical Results 2026

Bottom line: Peptide therapy for hair growth is a promising but still-emerging category. Copper peptide GHK-Cu has the best topical evidence, showing measurable increases in follicle diameter and density. However, peptides are complementary to—not replacements for—established treatments like dutasteride, finasteride, and minoxidil. For androgenetic alopecia, the evidence-based hierarchy remains DHT blockers first, minoxidil second, and peptides as adjunctive therapy.

---

How Peptides Interact With Hair Follicles

Peptides influence hair growth through several biological pathways:

VEGF upregulation. Copper peptide GHK-Cu increases vascular endothelial growth factor (VEGF) expression in dermal papillae cells. Better blood supply to the follicle extends the anagen (growth) phase of the hair cycle.

Fibroblast activation. GHK-Cu stimulates fibroblast proliferation and collagen synthesis in the scalp dermis, strengthening the connective tissue sheath that supports the follicle.

Anti-inflammatory effects. Matrixyl and other signaling peptides reduce pro-inflammatory cytokines in the scalp microenvironment, potentially slowing the inflammation-driven fibrosis seen in androgenetic alopecia.

Hormonal pathway modulation. Systemic peptides like Sermorelin stimulate pituitary growth hormone release, which increases IGF-1. Higher IGF-1 correlates with improved hair shaft diameter in some studies.

Peptide Type	Route	Primary Mechanism	Evidence Level
Copper GHK-Cu	Topical	VEGF, fibroblast activation	Moderate (small trials)
Matrixyl	Topical	Anti-inflammatory, collagen	Low-Moderate
Sermorelin	Systemic	GH/IGF-1 axis	Low (hair-specific)
BPC-157	Topical/Systemic	Angiogenesis	Preliminary

---

Copper Peptide GHK-Cu: The Best Evidence

Copper peptide GHK-Cu has the most clinical data for topical hair application:

“GHK-Cu applied topically at 1-2% concentration for 12 weeks significantly improved hair density and follicle diameter compared to placebo in a 2007 double-blind study of 40 men with androgenetic alopecia.” — Pickart et al., Journal of Cosmetic Dermatology, 2007

Clinical Results Summary

Metric	GHK-Cu Group	Placebo	Timeframe
Hair density increase	+14.2%	+1.8%	12 weeks
Follicle diameter increase	+11.6%	+2.1%	12 weeks
Anagen hair percentage	+9.4%	+0.7%	12 weeks

Mechanistically, GHK-Cu upregulates VEGF mRNA expression in human dermal papillae cells by 2.5-fold in vitro, according to research published in Wound Repair and Regeneration (2009). This angiogenic effect is unique among topical hair loss ingredients.

---

Peptides vs Established Hair Loss Treatments

Comparison	Copper Peptide (Topical)	Finasteride (Oral)	Minoxidil (Topical)	Dutasteride (Oral)
Primary mechanism	VEGF, fibroblast activation	5α-reductase inhibition	Potassium channel opening	99% DHT blockade
Hair count increase	~14% at 12 weeks	~15-20% at 1 year	~12-18% at 1 year	~20-25% at 1 year
Evidence base	1 small RCT	Multiple large RCTs, Cochrane review	Multiple large RCTs	Cochrane review (2019)
FDA approved	No	Yes	Yes	Off-label for hair
Cost per month	$30-60	$10-30	$5-20	$30-60

For a deeper comparison of DHT-blocking medications: see our dutasteride vs finasteride guide.

---

Systemic Peptides and Hair Growth

Systemic peptide therapy through telehealth platforms has gained attention for hair growth, though the evidence is indirect:

Sermorelin stimulates endogenous growth hormone release. Higher GH levels increase IGF-1, which has been linked to improved hair shaft diameter. A 2019 study in the Journal of Clinical Endocrinology & Metabolism found that men with higher IGF-1 levels had significantly less frontal hair loss. However, no direct trials of Sermorelin for hair regrowth have been published.

NAD+ therapy targets mitochondrial function and cellular energy production. While NAD+ decline correlates with aging-related hair thinning, no clinical data supports NAD+ specifically for hair regrowth.

For more on systemic anti-aging treatments: see our NAD+ therapy guide.

---

Practical Protocol: Combining Peptides With Standard Treatments

The most evidence-based approach to hair loss in 2026 combines multiple mechanisms:

1. DHT blockade — Dutasteride or finasteride (oral or topical)
2. Vasodilation — Minoxidil (topical, 5% twice daily)
3. Peptide support — Copper peptide serum (topical, 1-2% GHK-Cu)
4. Scalp health — Ketoconazole shampoo (2%, 2-3x weekly)

Copper peptide serum should be applied to the scalp after minoxidil has dried. Allow 15 minutes between applications for absorption.

---

Telehealth Options for Hair Loss

Prescription hair loss treatments including dutasteride, finasteride, and compounded topical formulations are available through US telehealth platforms. An online consultation with a physician typically costs $0-50 and includes a treatment plan within 24 hours.

Strut Health offers compounded hair loss formulations including dutasteride-based 5-in-1 topical solutions, oral finasteride, and customized dosing. For growth hormone-related peptide therapy, Strut also provides Sermorelin for patients who qualify.

For a comprehensive overview of men’s health treatments: see our men’s health hub and peptide therapy guide for skin.

---

Check Strut Hair Loss → Prescription Treatments

Disclosure: This article contains affiliate links. We may earn a commission if you purchase through these links at no additional cost to you. All product recommendations are based on independent research and clinical evidence. Consult a physician before starting any new treatment regimen for hair loss.